AstraZeneca have broken out the data they teased last month for transthyretin amyloidosis (ATTR) therapy eplontersen, showing that the drug was effective at slowing down d
An inquest in the UK has concluded that the death of a UK doctor in January 2021 shortly after being immunised against COVID-19 was a “rare and unintended complication” of
A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ovarian cancer drug Zejula, which competes with AZ’s top-selling PARP inhibito
AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed